Obstructive Uropathy Secondary to Antiretroviral Agents

Abstract

Acute kidney injury (AKI) and chronic kidney disease (CKD) are more common in HIV-infected patients than in the general population. We observed an HIV(+) young man who presents an unusual cause of acute renal injury (obstructive uropathy as a consequence of lithiases secondary to antiretroviral therapy). The differential diagnosis of kidney diseases associated with HIV infections includes: glomerular, tubular and interstitial causes. A renal biopsy is a useful tool in the diagnostic approach. Nephrologists and urologists must be aware of HIV-related renal affection, including toxicity related to HAART schedules.

Keywords: Acute kidney injury; HIV Obstructive uropathy; HAART toxicity

Introduction

Acute kidney injury (AKI) and chronic kidney disease (CKD) are more common in HIV-infected patients than in the general population. Hospitalized persons and those with several comorbidities are at higher risk or renal failure [1]. AKI is associated with an increased risk of heart failure, cardiovascular disease, end-stage renal disease (ESRD) and mortality [2]. Here, we report an HIV(+) adult male patient who developed acute renal injury secondary to obstructive uropathy as a consequence of antiretroviral therapy.

Case Report

A 33-year-old man was admitted to hospital with seizures due to cerebral toxoplasmosis. The patient’s past medical history was positive for HIV and Hepatitis B infections. While hospitalized, HAART (Tenofovir+lamivudine, atazanavir, ritonavir) and antiparasitic therapy were initiated. Within a month, he developed a febrile syndrome and CMV dissemination; treatment with ganciclovir was indicated. Abdominal ultrasound (US) and renal function were normal (creatinine 1.03 mg%). Three weeks later, he developed oliguric AKI (creatinine 5.39 mg). Urinary sediment showed some cells, WBC 6-8 per HPF, and microhematuria without proteinuria. His blood pressure was of 140/90 mm Hg. The differential diagnosis included: interstitial nephritis secondary to HAART, prerenal Acute Tubular Necrosis (the patient presented mild dehydration) and Drug toxicity. Tenofovir was discontinued. The immunological studies ANCA, Anti-DNA, Complement, and ANF were normal. A percutaneous renal biopsy was indicated. (Table 1) laboratory data.

The Renal US revealed a dilated aspect of the kidneys, and bilateral ureteral and pyelocaliceal ectasia, with the presence of bilateral lithiases in the ureteropelvic junction. CT scan confirmed both bilateral ureteropelvic ectasia (23mm) and lithiastic images (7.5 mm right kidney and 10 mm the left). There was a presence of dense material in both distal ureters. (Figure 1) The clinical picture was interpreted as obstructive AKI secondary to bilateral nephrolithiasis caused by HAART + Ganciclovir. A right double “J” catheter was inserted by cystoscopy; in the left ureter, a discharge of multiple small calculi was observed. Retrograde pyelogram did not show any obstructions at any level. The patient has discontinued Ganciclovir, and the treatment schedule was changed to include antiretroviral therapy without atazanavir. The patient developed post-obstructive polyuria, without hemodynamic or electrolyte abnormalities and he also showed a recovering normal renal function.
Obstructive Uropathy Secondary to Antiretroviral Agents

Differential diagnosis of AKI and CKD is mandatory (Table 2). The major renal diseases associated with HIV infection include glomerular, tubular and interstitial causes [3,4]. In HIV(+) patients, different clinical situations should be studied. The major renal diseases associated with HIV infection include glomerular, tubular and interstitial causes [3,4]. Differential diagnosis of AKI and CKD is mandatory (Table 2). CKD may be present in patients suffering from comorbidities like diabetes and hypertension and HIV-associated nephropathy is a possible renal complication in this population. Drug toxicity (tenofovir, indinavir) should also be taken into consideration. In the presence of AKI, pre-renal causes should be excluded (dehydration, non-HIV-related causes, and gastrointestinal diseases.) If parenchymal disease is suspected, glomerular injury (HIV related or drug induced) interstitial lesion (infection HIV-related: HIV or non-HIV related, or drug-induced) and tubulopathy should be discarded (drug-induced Fanconi Syndrome or nephrogenic diabetes insipidis, and viral tubular toxicity.) Systemic, urinary tract opportunistic infections and drug toxicity can cause AKI.

Table 2: Differential diagnosis of AKI and CKD is mandatory.

<table>
<thead>
<tr>
<th>Renal Diseases</th>
<th>Glomerular</th>
<th>Tubular</th>
<th>Interstitial</th>
</tr>
</thead>
</table>

Obstructive post-renal AKI may be secondary to drug induced tubular crystal deposition. Tenofovir toxicity causes a proximal tubulopathy which wastes phosphorus, glucose, amino acids and bicarbonate, which are normally reabsorbed. This damage is usually repaired when the drug is discontinued, but if it persists, it may lead to fibrosis and chronic lesions. Atazanavir and Indinavir can produce precipitation of crystals and develop inflammatory mechanisms and interstitial nephritis (risk factors include dehydration, alkaline urine pH, and previous lithiasis episodes). Patients with chronic hepatitis C coinfection have a greater risk of lithiasis. Indinavir-associated calculi are very small (2-6 mm) and they are usually eliminated, but tubular deposition may cause post-renal obstructive failure [4-6]. Ganciclovir is also nephrotoxic and it produces intratubular crystal precipitation.

Summary

We report an HIV-positive patient with an unusual cause of AKI. In this case, probable etiologies included drug toxicity (atazanavir and/or ganciclovir) in a person with multiple risk factors, such as hospitalization, dehydration and febrile syndrome. In the case of renal dysfunction, diagnostic studies in order to characterize etiology are urgent. Renal biopsy is a useful diagnostic procedure in these patients.

In HIV-positive patients, renal failure may be HIV-related, secondary to infections or their treatment and finally due to HAART side effects. Protease inhibitors and their lithogenic capacity may lead to modifications in HAART schedules [3,4]. Nephrologists and urologists must be aware of HIV-related renal diseases and toxicity of antiretroviral drugs.

References